Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCINE.L Regulatory News (CINE)

  • There is currently no data for CINE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Receipt of Anschutz written consent

2 Feb 2018 17:44

RNS Number : 8428D
Cineworld Group plc
02 February 2018
 

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

FOR IMMEDIATE RELEASE

 

Cineworld Group plc (the "Company")

Receipt of Anschutz written consent

2 February 2018

The Company is pleased to announce that The Anschutz Corporation, the largest shareholder of Regal Entertainment Group ("Regal"), has delivered its written consent to approve the acquisition of Regal by the Company (the "Acquisition"), and that this consent has become effective following the passing of the Resolutions at the General Meeting of the Company held earlier today. All Company and Regal shareholder approvals necessary to proceed with the Transaction have now been received, and completion of the Acquisition is currently expected to occur on or prior to 2 March 2018.

 

A copy of this announcement will be displayed shortly on the Company's website at www.cineworldplc.com.

Capitalised terms used in this announcement have the meanings given to them in the combined prospectus and class 1 circular dated 17 January 2018 (the "Prospectus"), which is available on the Company's website (www.cineworldplc.com) and may be inspected at the registered office of the Company at 8th Floor, Vantage London, Great West Road, Brentford TW8 9AG during normal business hours on any Business Day up to and including the date ofRe-admission.

For further details please contact:

Cineworld Group plc

+44 (0)20 8987 5000

Israel Greidinger

 

Nisan Cohen

 

 

 

 

 

 

 

Barclays (Joint Financial Adviser, Joint Underwriter, Joint Global Coordinator and Joint Corporate Broker to Cineworld)

+44 (0)20 7623 2323

Makram Azar

 

Daniel Ross

 

Mark Astaire

 

James Colburn

 

 

 

 

 

HSBC (Joint Financial Adviser, Joint Underwriter and Joint Global Coordinator to Cineworld)

+44 (0)20 7991 8888

Philip Noblet

 

Noam Kleinfeld

 

James Thomlinson

 

Mark Dickenson

 

Sam Barnett

 

 

 

Investec Bank plc (Sponsor, Joint Underwriter, Joint Bookrunner and Joint Corporate Broker to Cineworld)

+44 (0)20 7597 4000

 

 

Chris Sim

 

George Price

 

Jonathan Wynn

 

Robert Baker

 

 

 

 

 

Powerscourt (Public Relations Adviser to Cineworld)

+44 (0)20 7250 1446

 

 

Nick Dibden

 

Rob Greening

 

Lisa Kavanagh

 

 

IMPORTANT NOTICE

The contents of this announcement have been prepared by and are the sole responsibility of Cineworld.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

Neither the content of Cineworld's website nor any website accessible by hyperlinks on Cineworld's website is incorporated in, or forms part of, this announcement.

Each of Barclays Bank PLC, acting through its Investment Bank ("Barclays"), HSBC Bank plc ("HSBC") and Investec Bank plc ("Investec" and together with Barclays and HSBC, the "Underwriters") is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority. Each of the Underwriters is acting exclusively for Cineworld and no one else in connection with the Transaction or any other matter referred to in this announcement and will not be responsible to anyone other than Cineworld for providing the protections afforded to their respective clients nor for providing advice in relation to the Transaction or any other matter referred to in this announcement. Neither the Underwriters nor any of their respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of the Underwriters in connection with this announcement, any statements contained herein or otherwise.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares may decline and investors could lose all or part of their investment; the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Underwriters will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares and determining appropriate distribution channels.The person responsible for this announcement is Fiona Smith, Company Secretary of Cineworld.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSDFFIFIIT
Date   Source Headline
16th Mar 20164:35 pmRNSHolding(s) in Company
11th Mar 20169:44 amRNSHolding(s) in Company
10th Mar 20167:00 amRNSManagement Appointments
10th Mar 20167:00 amRNSPreliminary Results
1st Feb 201611:20 amRNSTotal Voting Rights
12th Jan 20167:00 amRNSTrading Update
4th Jan 20163:40 pmRNSTotal Voting Rights
15th Dec 201510:12 amRNSCineworld 2000 Screens Milestone
1st Dec 20152:18 pmRNSTotal Voting Rights and Home State Announcement
1st Dec 201512:47 pmRNSHolding(s) in Company
25th Nov 201510:45 amRNSBlocklisting listing six monthly return
24th Nov 20157:00 amRNSTrading Update
17th Nov 20159:30 amRNSAdditional Listing
2nd Nov 20152:00 pmRNSTotal Voting Rights
22nd Oct 201511:00 amRNSHolding(s) in Company
21st Oct 20158:00 amRNSAnalyst Visit
1st Oct 20152:11 pmRNSTotal Voting Rights
8th Sep 201511:05 amRNSDirector/PDMR Shareholding
1st Sep 20153:00 pmRNSTotal Voting Rights
19th Aug 20154:42 pmRNSDirector/PDMR Shareholding
13th Aug 20157:00 amRNSInterim Results
11th Aug 201510:15 amRNSHolding(s) in Company
4th Aug 201510:45 amRNSDirector/PDMR Shareholding
3rd Aug 20159:33 amRNSTotal Voting Rights
7th Jul 20157:00 amRNSTrading Update
1st Jul 201511:45 amRNSTotal Voting Rights
1st Jul 20159:00 amRNSNotice of Results
12th Jun 20152:14 pmRNSHolding(s) in Company
12th Jun 20152:12 pmRNSDirector/PDMR Shareholding
9th Jun 201511:24 amRNSManagement Changes
1st Jun 20152:30 pmRNSTotal Voting Rights
29th May 201510:36 amRNSDirector/PDMR Shareholding
28th May 20152:15 pmRNSAdditional Listing
27th May 20154:00 pmRNSBlocklisting six monthly return
27th May 20158:30 amRNSBoard Committees Changes & Director Appointment
26th May 20152:30 pmRNSResult of AGM
26th May 20157:01 amRNSTrading Update
12th May 201512:30 pmRNSDirector/PDMR Shareholding
1st May 20159:31 amRNSTotal Voting Rights
23rd Apr 20153:39 pmRNSDirector/PDMR Shareholding
21st Apr 20154:15 pmRNSAnnual Report and Notice of AGM
21st Apr 201510:30 amRNSDirector/PDMR Shareholding
1st Apr 201511:02 amRNSTotal Voting Rights
30th Mar 20152:00 pmRNSAdditional Listing
25th Mar 20154:00 pmRNSDirectorate Change
17th Mar 20151:16 pmRNSDirector/PDMR Shareholding
12th Mar 201510:43 amRNSHolding(s) in Company
12th Mar 20157:00 amRNSPreliminary Results
11th Mar 20159:36 amRNSDirectorate Change and Board Committees
4th Mar 20151:25 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.